Illustration of a person on front steps of their house putting shoes on in preparation for a hike as the inside of shoes next to him are on fire

Help your patients step into relief

Nevro HFXTM is the most effective treatment for refractory painful diabetic neuropathy (PDN).1

Request information

Learn more about Nevro HFX by speaking with our experts

Contact Us

Refer to a specialist

Contact professionals in your area that are treating patients with Nevro HFX

Find a Doctor

In the largest RCT of its kind, Nevro HFXTM demonstrated substantial and durable pain relief, as well as sensory improvement in the majority of patients.1

90% Responder Rate1 (≥50% relief)

80% Average Pain Relief1

65% Experienced Sensory Improvements1

Download: 24-Month PDN RCT Results in Diabetes Research and Clinical Practice

Finally, there’s an FDA-approved nonpharmacological treatment for painful diabetic neuropathy. Patients can try it before they decide, in a one-week temporary trial to evaluate their individual relief.

Proven to effectively treat chronic pain for over 10 years in 100,000 patients. Now proven safe and effective for patients with diabetes.

At 24 months, the infection rate of just 5.2% (8 of 152 implanted patients) was consistent with reports for other SCS procedures.1

Frequently Asked Questions: Patient Access

Is SCS covered under Medicare?
FAQ toggle button
  • SCS is covered under the Medicare Part B benefit
  • Spinal cord stimulation is broadly covered by a National Coverage Decision for “chronic tractable pain of the trunk and limbs” with more specific local coverage determinations for some Medicare Administrative Contractors (MACs)
  • SCS trial and implant procedures do not require prior authorization except when done in the Hospital Outpatient setting
How is SCS covered under a commercial health plan?
FAQ toggle button
  • SCS is covered under the medical benefit of the health plan
  • Spinal cord stimulation is broadly covered by all major commercial health plans with specific coverage language and indications varying by plan type
  • Prior authorization of the SCS trial and implant procedure is typically required for all commercial health plans
How is individual patient coverage determined?
FAQ toggle button
  • A Nevro HFX implanting physician will be able to determine appropriateness of HFX for their PDN patients
  • Due to medical necessity requirements, a detailed clinical history of tried and failed conservative therapies will be needed to facilitate access during the prior authorization process
  • Individual out of pocket amounts will be determined during benefit investigations and will be based upon individual plan details, deductible limits, and out of pocket maximum amounts
HFX is covered by all major commercial insurance plans, Medicare, Medicaid, and Tricare.

Downloadable resources

Referral Guide


Patient Discussion Guide


Additional Resources


Access to the clinical evidence portfolio supporting 10 kHz Therapy

Product Manuals

Instructions for use and product manuals, including MRI guidelines


Services to support reimbursement and patient access to Nevro products

Request more information

Learn more about Nevro HFX by speaking with our experts.

Contact Us

Follow Us On